Dashenlin Pharm Grp Co Ltd (603233) - Cash Flow Conversion Efficiency

Latest as of September 2025: 0.096x

Based on the latest financial reports, Dashenlin Pharm Grp Co Ltd (603233) has a cash flow conversion efficiency ratio of 0.096x as of September 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (CN¥818.72 Million ≈ $119.80 Million USD) by net assets (CN¥8.49 Billion ≈ $1.24 Billion USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.

Dashenlin Pharm Grp Co Ltd - Cash Flow Conversion Efficiency Trend (2012–2024)

This chart illustrates how Dashenlin Pharm Grp Co Ltd's cash flow conversion efficiency has evolved over time, based on yearly financial data. Read 603233 current and long-term liabilities for a breakdown of total debt and financial obligations.

Dashenlin Pharm Grp Co Ltd Competitors by Cash Flow Conversion Efficiency

The table below lists competitors of Dashenlin Pharm Grp Co Ltd ranked by their cash flow conversion efficiency.

Company	Cash Flow Conversion Efficiency
Angel One Limited NSE:ANGELONE	0.035x
Shaanxi Huaqin Technology Industry Co. Ltd. A SHG:688281	N/A
Marathon Digital Holdings Inc NASDAQ:MARA	-0.038x
Vapores SN:VAPORES	-0.073x
Bank of Hawaii Corporation NYSE:BOH	0.021x
Wuxi Taiji Industry Co Ltd SHG:600667	0.016x
Dyne Therapeutics Inc NASDAQ:DYN	-0.115x
Enerjisa Enerji AS IS:ENJSA	0.063x

Annual Cash Flow Conversion Efficiency for Dashenlin Pharm Grp Co Ltd (2012–2024)

The table below shows the annual cash flow conversion efficiency of Dashenlin Pharm Grp Co Ltd from 2012 to 2024. For the full company profile with market capitalisation and key ratios, see Dashenlin Pharm Grp Co Ltd market capitalisation.

Year	Net Assets	Operating Cash Flow	Cash Flow Conversion Efficiency	Change
2024-12-31	CN¥8.14 Billion ≈ $1.19 Billion	CN¥3.11 Billion ≈ $454.55 Million	0.382x	-4.60%
2023-12-31	CN¥7.93 Billion ≈ $1.16 Billion	CN¥3.17 Billion ≈ $464.43 Million	0.400x	-26.90%
2022-12-31	CN¥6.86 Billion ≈ $1.00 Billion	CN¥3.76 Billion ≈ $549.70 Million	0.547x	+108.91%
2021-12-31	CN¥5.94 Billion ≈ $868.61 Million	CN¥1.55 Billion ≈ $227.54 Million	0.262x	-25.28%
2020-12-31	CN¥5.57 Billion ≈ $815.49 Million	CN¥1.95 Billion ≈ $285.92 Million	0.351x	-11.07%
2019-12-31	CN¥4.33 Billion ≈ $633.86 Million	CN¥1.71 Billion ≈ $249.90 Million	0.394x	+39.29%
2018-12-31	CN¥3.09 Billion ≈ $451.68 Million	CN¥873.64 Million ≈ $127.84 Million	0.283x	+23.87%
2017-12-31	CN¥2.80 Billion ≈ $410.12 Million	CN¥640.39 Million ≈ $93.71 Million	0.228x	-38.12%
2016-12-31	CN¥1.34 Billion ≈ $196.39 Million	CN¥495.60 Million ≈ $72.52 Million	0.369x	-19.52%
2015-12-31	CN¥1.02 Billion ≈ $149.43 Million	CN¥468.59 Million ≈ $68.57 Million	0.459x	-41.20%
2014-12-31	CN¥574.85 Million ≈ $84.12 Million	CN¥448.58 Million ≈ $65.64 Million	0.780x	+59.72%
2013-12-31	CN¥589.93 Million ≈ $86.32 Million	CN¥288.22 Million ≈ $42.18 Million	0.489x	-35.64%
2012-12-31	CN¥381.11 Million ≈ $55.77 Million	CN¥289.31 Million ≈ $42.34 Million	0.759x	--

About Dashenlin Pharm Grp Co Ltd

SHG:603233 China Biotechnology

Market Cap

$3.11 Billion

CN¥21.26 Billion CNY

Market Cap Rank

#4859 Global

#922 in China

Share Price

CN¥18.67

Change (1 day)

-0.27%

52-Week Range

CN¥15.58 - CN¥21.27

All Time High

CN¥57.53